Dynacure

Dynacure is a biotechnology company developing new therapeutic approaches for patients with serious orphan diseases. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM). The Dyn101 development program of Dynacure is based on modulating the expression of dynamin 2 protein using antisense oligonucleotides developed in collaboration with Ionis Pharmaceuticals. We are initially focused on developing new therapies to address myotubular and centronuclear myopathies (CNM), a group of congenital myopathies characterized by severe muscle weakness, genetic heterogeneity, and defects in the structural organization of muscle fibers. CNM is marked by the presence of centralized or central nuclei within muscle cells. In healthy muscle cells, nuclei are typically located at the periphery of the cell.